Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celcuity and other ETFs, options, and stocks.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
87
Employees87
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
87
Employees87

CELC Key Statistics

Market cap
4.64B
Market cap4.64B
Price-Earnings ratio
-27.34
Price-Earnings ratio-27.34
Dividend yield
Dividend yield
Average volume
887.94K
Average volume887.94K
High today
$102.58
High today$102.58
Low today
$99.35
Low today$99.35
Open price
$101.24
Open price$101.24
Volume
768.51K
Volume768.51K
52 Week high
$112.64
52 Week high$112.64
52 Week low
$7.58
52 Week low$7.58

Stock Snapshot

The current Celcuity(CELC) stock price is $100.39, with a market capitalization of 4.64B. The stock trades at a price-to-earnings (P/E) ratio of -27.34.

As of 2025-12-16, Celcuity(CELC) stock has fluctuated between $99.35 and $102.58. The current price stands at $100.39, placing the stock +1.1% above today's low and -2.1% off the high.

Celcuity(CELC) shares are trading with a volume of 768.51K, against a daily average of 887.94K.

In the last year, Celcuity(CELC) shares hit a 52-week high of $112.64 and a 52-week low of $7.58.

In the last year, Celcuity(CELC) shares hit a 52-week high of $112.64 and a 52-week low of $7.58.

CELC News

Simply Wall St 1d
Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s Investment Narrative?

Celcuity Inc. recently reported updated Phase 3 VIKTORIA-1 results for its PAM inhibitor gedatolisib in HR+/HER2-, PIK3CA wild-type advanced breast cancer, high...

Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s Investment Narrative?
TipRanks 5d
Celcuity initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Celcuity (CELC) with an Overweight rating and $126 price target Claim 50% Off TipRanks Premium and Invest with Confidence Un...

Simply Wall St 6d
Is Celcuity’s Huge 2025 Rally Justified by Its Long Term Cash Flow Potential?

Wondering if Celcuity at around $101 a share is still a smart buy after its huge run, or if you are late to the party? This breakdown will help you decide wheth...

Is Celcuity’s Huge 2025 Rally Justified by Its Long Term Cash Flow Potential?

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.